Updates on 2.5% iPAAG (Polyacrylamide Hydrogel)
In our latest webinar, a number of expert practitioners discussed the latest findings of the use of 2.5% iPAAG (Arthramid) and upcoming advances.
EquiManagement has summarised the webinar in their blog below, which covers the latest findings on the use of 2.5% iPAAG (Arthramid®) for joint treatment, the mechanism of action, its treatment success rates, timeframe for success, and upcoming research.
Read the full article by EquiManagement HERE
